IntelGenx CEO speaks to the potential impact of Montelukast on Alzheimers
In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT) discusses the invention of their pharmaceutical oral film, VersaFilm™ and its drug delivery technology advantage. Dr. Zerbe says that their “objective is to improve the efficacy of a drug and its availability in the body.” Utilizing the VersaFilm™ technology, he comments upon IntelGenx’s experimentation with the drug commonly used to treat asthma — Montelukast.
He comments: “We discovered Montelukast as a great asset management opportunity. Montelukast has been approved for many years as a treatment for asthma. There is very, very impressive research that was recently published indicating that it could be a very effective Alzheimer’s treatment. That is very important for the patient because today there is no treatment available that can reverse the effects of the Alzheimer’s disease, but Montelukast has the potential to do that.” — To access the full interview, click here
Disclaimer: IntelGenx Technologies Corp. is an advertorial member of InvestorIntel Corp.
Get our daily investorintel update
InvestorIntel is a trusted source of reliable information at the forefront of emerging markets that brings investment opportunities to discerning investors.